Will the Alfred E. Mann Institutes focus on any specific areas of biomedical research?
It is anticipated that many of the AMIs may wish to develop specific areas of expertise based on the special intellectual capital that is resident within each university. Mr. Mann desires that the technologies to be included in the portfolio of AMI product enablement be diverse and has requested that the Site Selection Committee not focus on any specific area of biomedical technology research or disease but rather on the quality and potential of the research efforts. Thus the AMIs will not have a focused association with a particular technology or disease states (i.e., nanotechnology, diabetes, colon cancer, etc.) but are intended to explore the broad area of the biomedical sciences and cognate areas for commercial development and to be responsive to technologies and discoveries many years into the future.
